Icade (ICAD) Panoramica del titolo
Icade è una società immobiliare a servizio completo con competenze sia nell'investimento in immobili commerciali (portafoglio del valore di 6,8 miliardi di euro su base consolidata al 31.12.2023) sia nello sviluppo immobiliare (ricavi economici al 2023 di 1,3 miliardi di euro) che opera in tutta la Francia. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 5/6 |
| Crescita futura | 3/6 |
| Prestazioni passate | 0/6 |
| Salute finanziaria | 3/6 |
| Dividendi | 3/6 |
ICAD Community Fair Values
Create NarrativeSee what 22 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Concorrenti di Icade
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | €18.65 |
| Massimo di 52 settimane | €23.06 |
| Minimo di 52 settimane | €18.09 |
| Beta | 0.90 |
| Variazione di 1 mese | -12.61% |
| Variazione a 3 mesi | -9.47% |
| Variazione di 1 anno | -9.29% |
| Variazione a 3 anni | -49.49% |
| Variazione a 5 anni | -74.35% |
| Variazione dall'IPO | -27.44% |
Notizie e aggiornamenti recenti
ICAD: Cautious Outlook And Special Meeting Timing Will Shape Balanced Future
Analysts have nudged their fair value estimate for Icade from €21.31 to €21.67, reflecting a slightly higher €22 price target and a view that the stock now presents more limited downside at current levels. What’s in the News for Icade Icade has scheduled a Special and Extraordinary Shareholders Meeting for June 10, 2026.
ICAD: Limited Downside View Will Still Pressure Shares Going Forward
Analysts have raised their fair value estimate for Icade from €16.30 to €17.00, citing a higher Street price target of €22 and the view that downside risk at current levels now appears more limited. What's in the News Icade has scheduled a Special and Extraordinary Shareholders Meeting for June 10, 2026, at the Coeur Defense building, Tour B Espace Comet, 24th floor, 100 Esplanade du General de Gaulle, Paris La Defense Cedex, France.Recent updates
ICAD: Cautious Outlook And Special Meeting Timing Will Shape Balanced Future
Analysts have nudged their fair value estimate for Icade from €21.31 to €21.67, reflecting a slightly higher €22 price target and a view that the stock now presents more limited downside at current levels. What’s in the News for Icade Icade has scheduled a Special and Extraordinary Shareholders Meeting for June 10, 2026.ICAD: Limited Downside View Will Still Pressure Shares Going Forward
Analysts have raised their fair value estimate for Icade from €16.30 to €17.00, citing a higher Street price target of €22 and the view that downside risk at current levels now appears more limited. What's in the News Icade has scheduled a Special and Extraordinary Shareholders Meeting for June 10, 2026, at the Coeur Defense building, Tour B Espace Comet, 24th floor, 100 Esplanade du General de Gaulle, Paris La Defense Cedex, France.ICAD: Slower Healthcare Exit And Paused Special Payouts Will Shape Balanced Outlook
Analysts have nudged their fair value estimate for Icade slightly lower to about €21.31. This reflects a reduced price target and updated assumptions around slower revenue growth, a modestly softer profit margin, a higher discount rate and the view that asset disposals and potential special dividends may take longer to materialise.ICAD: Slower Healthcare Disposal And Halted Special Payouts Will Pressure Shares
Analysts have reduced their price target on Icade from €30 to €25, citing expectations that the healthcare business disposal could take longer and that special dividends are no longer assumed over the next three years. Analyst Commentary Bearish analysts are flagging a more cautious stance on Icade, with recent research pointing to timing and payout uncertainties that weigh on sentiment.ICAD: Slower Healthcare Disposal And Lost Special Dividends Will Pressure Shares
Analysts have trimmed their price target for Icade to €25 from €30, reflecting expectations that the planned disposal of the healthcare business may take longer and that special dividends are no longer assumed over the next three years. Analyst Commentary Bearish analysts have shifted to a more cautious stance on Icade, with the rating cut to Equal Weight from Overweight and the price target moved to €25 from €30.ICAD: Slower Healthcare Disposal And Missing Special Dividends Will Shape Fair Outlook
Narrative Update The analyst price target for Icade has been trimmed to €21.35 from €21.54. This reflects a more cautious stance from analysts after recent downgrades and expectations that healthcare asset disposals and potential special dividends may take longer to play out.
ICAD: Slower Healthcare Exit And Reset Distributions Will Support Future Repricing
Analysts have trimmed their fair value estimate for Icade to about €29.91 from €31.29, echoing recent price target cuts, such as the move from €30 to €25, as they factor in a longer timeline for healthcare asset disposals and the absence of expected special dividends. Analyst Commentary The recent research updates on Icade point to a more cautious stance as analysts reassess how quickly the group can execute on its healthcare disposals and how generous future shareholder returns might be.ICAD: Slower Healthcare Disposals And Lost Special Dividends Will Shape Fairly Valued Outlook
Analysts have modestly trimmed their fair value estimate for Icade from €22.03 to about €21.54. This reflects updated views on slower progress on healthcare disposals, a higher required discount rate and the removal of assumed special dividends after recent downgrades and price target cuts on the stock.ICAD: Higher Office Risk Premium Will Set Stage For Future Repricing
Analysts have reduced their fair value estimate for Icade from about €36.67 to about €31.29, reflecting a higher assumed discount rate and lower profit margin expectations following recent rating cuts and a lower €18 Street price target. Analyst Commentary Recent rating actions on Icade have leaned cautious, with cuts to both recommendations and price targets that feed into the lower fair value estimate.ICAD: Office Risk Repricing And Downgrades Will Shape Fairly Valued Outlook
Analysts have trimmed their fair value estimate for Icade from €23.33 to €22.03. This reflects a slightly higher discount rate, a modestly lower profit margin outlook and recent downgrades that cite a higher perceived equity risk premium in offices.ICAD: Office Risk Repricing And Downgrades Will Shape Future Share Performance
Analysts have trimmed their fair value estimate for Icade from about €23.46 to roughly €23.33, citing slightly higher required returns, more cautious assumptions on revenue growth and profit margins, and recent Street downgrades, including a cut in one price target from €25 to €18. Analyst Commentary Bullish Takeaways Bullish analysts may see the recent pullback in fair value and price targets as already reflecting higher equity risk premiums in offices, which can limit further downside if execution on existing projects is steady.ICAD: Office Downgrades And Higher Risk Premium Will Pressure Shares
Analysts have trimmed their price expectations for Icade to around €14.60, reflecting recent rating downgrades and a higher equity risk premium for office assets. This has been incorporated into updated assumptions for revenue growth, profit margins and future P/E levels.ICAD: Office Risk Repricing Will Shape Margins And Share Performance
Analysts have lowered their price target on Icade from EUR 25 to EUR 18. This reflects a higher perceived equity risk in offices, alongside slightly faster expected revenue growth but weaker profit margins and a higher valuation multiple.ICAD: Office Weakness And Higher Equity Risk Will Pressure Shares
Analysts have cut their price target on Icade from EUR 17.80 to EUR 14.60, reflecting a lower revenue growth outlook and higher perceived equity risk in offices, even as profit margins are expected to improve. Analyst Commentary Bearish analysts have recently shifted their stance on Icade, highlighting a weaker outlook for office assets and increasing caution around the company’s equity risk profile.
Pulse Building Lease With Seine-Saint-Denis Will Boost Portfolio Strength
Improved rental growth expected from the lease agreement and focus on prime locations may enhance revenue stability.A Look At Icade's (EPA:ICAD) Share Price Returns
Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. When you...How Did Icade SA's (EPA:ICAD) 8.0% ROE Fare Against The Industry?
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...Rendimenti per gli azionisti
| ICAD | FR REITs | FR Mercato | |
|---|---|---|---|
| 7D | -1.8% | -0.7% | -1.5% |
| 1Y | -9.3% | -0.9% | 2.3% |
Ritorno vs Industria: ICAD ha avuto una performance inferiore rispetto al French REITs che ha registrato un rendimento -0.9 % nell'ultimo anno.
Rendimento vs Mercato: ICAD ha avuto una performance inferiore al mercato French che ha registrato un rendimento 2.3 % nell'ultimo anno.
Volatilità dei prezzi
| ICAD volatility | |
|---|---|
| ICAD Average Weekly Movement | 3.9% |
| REITs Industry Average Movement | 2.4% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in FR Market | 10.8% |
| 10% least volatile stocks in FR Market | 2.5% |
Prezzo delle azioni stabile: ICAD non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato French.
Volatilità nel tempo: La volatilità settimanale ( 4% ) di ICAD è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 1954 | 981 | Nicolas Joly | www.icade.fr |
Icade è una società immobiliare a servizio completo con competenze sia nell'investimento in immobili commerciali (portafoglio del valore di 6,8 miliardi di euro su base consolidata al 31.12.2023) sia nello sviluppo immobiliare (ricavi economici al 2023 di 1,3 miliardi di euro) che opera in tutta la Francia. Icade ha creato partnership a lungo termine per rispondere alle tendenze emergenti del settore. Ha posto le questioni climatiche e la conservazione della biodiversità al centro del suo modello di business per reinventare il settore immobiliare e contribuire a città più sostenibili.
Icade Riepilogo dei fondamenti
| ICAD statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | €1.41b |
| Utili (TTM) | -€123.00m |
| Ricavi(TTM) | €1.34b |
ICAD è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| ICAD Conto economico (TTM) | |
|---|---|
| Ricavi | €1.34b |
| Costo del fatturato | €871.10m |
| Profitto lordo | €465.80m |
| Altre spese | €588.80m |
| Utili | -€123.00m |
Ultimi utili riportati
Dec 31, 2025
Prossima data di guadagno
Jul 21, 2026
| Utile per azione (EPS) | -1.62 |
| Margine lordo | 34.84% |
| Margine di profitto netto | -9.20% |
| Rapporto debito/patrimonio netto | 110.3% |
Come si è comportato ICAD nel lungo periodo?
Vedi performance storica e confrontoDividendi
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/07/13 01:45 |
| Prezzo dell'azione a fine giornata | 2026/07/13 00:00 |
| Utili | 2025/12/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Icade è coperta da 18 analisti. 11 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Celine Huynh | Barclays |
| Paul May | Barclays |
| Aaron Guy | Barclays |